skip to main content
Close Icon We use cookies to improve your website experience.  To learn about our use of cookies and how you can manage your cookie settings, please see our Cookie Policy.  By continuing to use the website, you consent to our use of cookies.
Global Search Configuration
  • Close Icon
Whilst many market observers predicted a reduction in investor appetites for life science initial public offerings at the end of 2015, investors continued to support life sciences IPOs globally in 2016. What really set 2016 apart from previous years was both the global diversity of the offerings – the US was no longer as dominant as it once was for biotech IPOs – and the fact that the top three offerings accounted for more than two thirds of the total sums raised.







電話:+81 (0)3 6273 4260